Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Q1FY24 Review: Eris Lifesciences: Targeting to accelerate organic growth

8 Aug 2023 , 01:03 PM

Eris’ Q1 revenue growth was muted, with high-single-digit growth on an organic basis in the India business (analysts of IIFL Securities estimate 7-8% YoY). However, mgmt’s execution in the acquired derma portfolio has been strong with Oaknet’s Ebitda margins improving QoQ from 27% to 35%, while the Ebitda drag from the Insulin business also halved QoQ. With a strong launch pipeline of 7-8 new products in H2FY24 (4 combination products, 2 at-risk opportunities, and 2 injectable diabetes products), Eris is targeting to further expand its CVM (covered market presence) and outperform IPM growth by 400bps with organic growth in Eris’ portfolio expected to accelerate to lowdouble-digits going forward. Analysts of IIFL Securities largely maintain their estimates of 14/19% revenue/Ebitda Cagr over FY23-26 and reiterate their BUY rating. Their TP of Rs880 is pegged at ~25x 2YF EPS. 

Eris’ India Branded business (excl. TGx) grew 21% YoY in Q1, aided by the acquisitions of derma portfolio from Oaknet, Glenmark and Dr. Reddy’s. Analysts of IIFL Securities estimate that Eris’ organic India business (incl. TGx) grew 7-8% YoY in Q1. Mgmt attributed muted organic growth to overall market growth being weak in Q1. While Oaknet’s Ebitda margins improved QoQ, Eris has been able to retain 75% of the business acquired from GNP/DRRD in the first quarter of integration and expects to start capturing 100% of the GNP/DRRD portfolio sales from Q2FY24. 

Strong pipeline of 7-8 new product launches in H2FY24, with Eris targeting to launch 4 combination products in diabetes/cardiac/neurology space (from its pipeline of 10 products) in Q3/Q4FY24, 2 at-risk opportunities of Linagliptin and FCM injection, and 2 more injectable diabetes products of Glargine and Liraglutide in Q4FY24. These launches, along with benefit of India price hikes from Q2, should enable Eris to accelerate the organic growth in its India portfolio to low-double-digits. Analysts of IIFL Securities forecast 10.7% Cagr in Eris’ organic India sales over FY23-26. 

Mgmt has reiterated its Ebitda margin guidance of ~35% for FY24 (vs 36.4% in Q1), as GM dilution in H2FY24 owing to new product launches and R&D investment of Rs300m for 10 pipeline combination products will be offset by continued margin improvement in the base India business, current profitability sustaining in Oaknet/acquired portfolio, and Ebitda break-even expected in the Insulin biz by Q4FY24.

Related Tags

  • Eris Lifesciences
  • Eris Lifesciences Q1
sidebar mobile


Read More

Most Read News

Sensex and Nifty close in Red
24 Jul 2024|04:29 PM
M&M Finance Q1 net profit up by 45% y-o-y
24 Jul 2024|05:59 PM
Over 23 Lakh New Enrollments for ESIC in May
24 Jul 2024|01:34 PM
Read More
Knowledge Centerplus

Logo IIFL Customer Care Number
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

Knowledge Centerplus

Follow us on


2024, IIFL Securities Ltd. All Rights Reserved

  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account." is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.